Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. April 2026 11:00 ET | Quelle: Crohn's and Colitis Canada

Le programme de bourses d'études MII d’AbbVie fête ses 15 ans : les candidatures sont ouvertes pour 2026

TORONTO, 02 avr. 2026 (GLOBE NEWSWIRE) -- Crohn et Colite Canada et AbbVie sont heureux d'annoncer l'ouverture des candidatures pour le Programme de bourses d'études MII d’AbbVie 2026. Cette année...
02. April 2026 11:00 ET | Quelle: Crohn's and Colitis Canada

AbbVie IBD Scholarship Program Marks 15 Years: Applications Open for 2026

Crohn’s and Colitis Canada and AbbVie open applications for the 2026 AbbVie IBD Scholarship, marking 15 years of supporting students living with IBD.
23. März 2026 16:05 ET | Quelle: Abivax

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis...
03. März 2026 09:16 ET | Quelle: Mount Sinai Press Office

Mount Sinai and King Saud University Medical City Forge a Three-Year Collaboration to Advance Precision Medicine in Familial Inflammatory Bowel Disease

New York, March 03, 2026 (GLOBE NEWSWIRE) -- [New York, NY, and Riyadh, Saudi Arabia [March 3, 2026] — Mount Sinai and King Saud University Medical City in Riyadh, Saudi Arabia, today announced a...
25. Februar 2026 08:00 ET | Quelle: Curanex Pharmaceuticals Inc

Curanex Provides Operational Update on Key Regulatory Milestones

Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX)...
24. Februar 2026 07:03 ET | Quelle: Research and Markets

Inflammatory Bowel Disease Treatment Market Competitive Landscape Report 2025: Top Players Analysis, Profiles, Strategic Developments, Mergers, Product Launches, Sustainability Goals, Revenue Insights

Dublin, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Market Company Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights,...
21. Februar 2026 06:00 ET | Quelle: Abivax

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at...
17. Februar 2026 08:45 ET | Quelle: Palisade Bio, Inc.

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 ...
16. Januar 2026 08:30 ET | Quelle: Palisade Bio, Inc.

Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences

PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq:...
07. Januar 2026 08:15 ET | Quelle: Palisade Bio, Inc.

Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and...

Nächste Seite